MedTrace Logo

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

NCT03579082 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-09-14

No results posted yet for this study

Summary

To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP for patients with replase and refractory Diffuse Large B cell lymphoma.

Conditions

Interventions

DRUG

Decitabine

Given ivgtt

Sponsors & Collaborators

  • Mingzhi Zhang

    lead OTHER

Principal Investigators

  • Mingzhi Zhang · The first affilliated hospital of zhengzhou university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-06-01
Completion
2019-12-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03579082 on ClinicalTrials.gov